triplet nda submiss watch start updat pt
vertex report success phase program efficaci
triplet regimen like success phase triplet program report
late novemb efficaci continu solid line
howev similar minor hetmin patient
pass safeti evalu forc wait review
data choos candid regulatori file review
nejm phase studi manag
commentari posit tone around safeti press releas lead us believ
one candid file stay bullish increas pt
press releas state given similar data
week primari efficaci endpoint regimen
near-term avail final data regimen opco
emphasi vertex plan util final data choos best
regimen submit regulatori approv global
believ nejm phase data supplementari appendix
page supplementari appendix page clearli
demonstr slightli differ benefit/risk profil two triplet henc
manag need extra time determin molecul take
forward laud prudenc
high-level analysi indic potenti slightli
better efficaci among hetmin patient popul slightli
better safeti profil howev seem perform slightli better among
homozyg patient dose lower potenti
offer better therapeut index futur combo
manag commentari earn call suggest
exposure/respons relationship higher dose mimic
dose howev seem consist slightli
advers event phase studi patient popul
size phase studi
recent wrote street could potenti underestim
sales/earn power next three five year investor
could wait clear triplet benefit/risk profil prior file
increas exposur name believ time
year price histori
global biotechnolog
compani discov develop
seriou diseas
analyst certif import disclosur see disclosur
orkambi achiev patient penetr homozyg
symdeko tez/iva success approv get
homozyg penetr
slower expect eu launch orkambi franc
price
triplet late-stag clinic trial news flow
provid visibl pipelin beyond cf
rate vertex outperform price target
compani posit deliv strong sale earn
growth next five year potenti even
greater growth near- tezacaftor/ivacaftor mid-term triplet
therapi homozyg cf patient
product launch outperform opex reach steadi state
could begin upsid stori believ
orkambi/symdeko reimburs approv addit ex-
us countri uk/france/etc us approv symdeko age
year kalydeco infant month
phase data updat safeti
updat one/day triplet updat next-gen
pipelin project phase scd beta-th phase
ind fsg candid
submit nda triplet regimen
vertex secur broad reimburs cf franchis ex-u
rapidli expect
symdeko sale ramp faster expect
triple-combin regimen tez/iva plu anoth corrector
approv market hetmin popul
disclos addit pipelin opportun
failur secur cf regulatori approvals/reimburs ex-u
lower expect uptak orkambi/symdeko
compet regimen other abbvie/galpago
approv earlier expect take signific market share
pt util composit valuat methodolog biotech compani util forward p/
 multipl npv adj estim earn sinc biotech high-growth/high-expect sector aim rank target
compani base qualiti sale and/or earn growth vs peer group peer index nbi expect
earn growth next three five year well expect higher termin multipl
due perceiv greater certainti qualiti sales/earn growth appli discount rate vs peer group average
slow cf sale disappoint commerci launch penetr tezacaftor/ivacaftor pipelin failur triplet regimen and/
regulatori non-approv kalydeco label extens
revenu compound-annual-growth-rate net profit/loss y/i growth share count compound-annual-growth-rate us adj ep compound-annual-growth-rate group index nbi indexp group adj ep compound-annual-growth-rate expect nbi index ep ltg cagrpeer group termin multipl price-to-earnings peer group beg us termin multipl peer group multipl compound-annual-growth-rate peer grouptermin valu us wacc peer group larg cap biotech averag us discount rate adj ep price-to-earnings valuat vertex pharmaceut
statement revenu royalti revenu collabor total product royalti research develop sale gener administr restructur expenses- intang asset impair charges- total cost expens incom loss oper interest incom net- interest expens incom expens incom loss provis benefit incom tax provis benefit incom provis non-cash taxes- net incom loss net incom loss attribut vertex dilut share outstand outperform
stock price compani mention report
